Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier

Journal of Pharmaceutical Sciences

Volumn 97, Issue 12, 2008, Pages 5386-5400

  Syvänen, Stina ^a,b   Hooker, Andrew ^a   Rahman, Obaidur ^b   Wilking, Helena ^b   Blomquist, Gunnar ^a   Långström, Bengt ^a,b   Bergström, Mats ^a,c   Hammarlund Udenaes, Margareta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BIACORE AB   (Sweden)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Active transport; Blood brain barrier; Drug interactions; Efflux pumps; Metabolism; P glycoprotein; PET; Pharmacokinetic pharmacodynamic models; Pharmacokinetics; Population pharmacokinetics pharmacodynamics

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; VERAPAMIL;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; COMPARTMENT MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG TRANSPORT; ISOTOPE LABELING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT;

EID: 57349085135     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21359     Document Type: Article

References (24)

1. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J. 1992. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51:1427-1437.
2. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
3. Bergström M, Fasth KJ, Kilpatrick G, Ward P, Cable KM, Wipperman MD, Sutherland DR, Långström B. 2000. Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171 - PET studies in rhesus monkey. Neuropharmacology 39:664-670.
4. Lammertsma AA. 2002. Radioligand studies: Imaging and quantitative analysis. Eur Neuropsychopharmacol 12:513-516.
5. Chikhale EG, Burton PS, Borchardt RT. 1995. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: Kinetic evidence for an apically polarized efflux mechanism. J Pharmacol Exp Ther 273:298-303.
6. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, Vaalburg W, Franssen EJ. 1999. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 59:2411-2416.
7. Bart J, Willemsen AT, Groen HJ, van der Graaf WT, Wegman TD, Vaalburg W, de Vries EG, Hendrikse NH. 2003. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage 20:1775-1782.
8. Syvänen S, Blomquist G, Sprycha M, Höglund AU, Roman M, Eriksson O, Hammarlund-Udenaes M, Långström B, Bergström M. 2006. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 32:1134-1141.
9. Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, Obayashi S, Nakao R, Suzuki K, Sugiyama Y, Suhara T. 2006. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther 316:647-653.
10. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD. 2005. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503-514.
11. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, Unadkat JD. 2006. Verapamil P-glycoprotein transport across the rat blood-brain barrier: Cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 317:704-710.
12. Luurtsema G, Windhorst AD, Mooijer MP, Herscheid JD, Lammertsma AA, Franssen EJ. 2002. Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring P-glycoprotein function with positron emission tomography. J Label Comp Radiopharm 45:1199-1207.
13. Salvatore RN, Nagle KW, Jung J. 2002. Cesium effect: High chemoselectivity in direct N-alkylation of amines. J Org Chem 67:674-683.
14. Teodori E, Dei S, Quidu P, Budriesi R, Chiarini A, Garnier-Suillerot A, Gualtieri F, Manetti D, Romanelli MN, Scapecchi S. 1999. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: Discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. J Med Chem 42:1687-1697.
15. Im DS, Cheong CS, Lee SH, Park H, Youn BH. 1999. Enzyme-catalysed improved resolution of (RS)-4-cyano-4-(3,4-dimethoxyphenyl)-4-isopropyl-1- butanol. Tetrahedron Asym 10(19):3759-3767.
16. Jonsson EN, Karlsson MO, Wilkins JJ, Hooker A. 2005. Xpose4. http://xposesourceforgenet/.
17. Golden PL, Pollack GM. 1998. Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain. Biopharm Drug Dispos 19:263-272.
18. Syvänen S, Xie R, Sahin S, Hammarlund-Udenaes M. 2006. Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res 23:705-717.
19. Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
20. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM. 1990. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265:3975-3980.
21. Higgins CF, Gottesman MM. 1992. Is the multidrug transporter a flippase? Trends Biochem Sci 17:18-21.
22. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. 1993. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268:21493-21496.
23. Dagenais C, Graff CL, Pollack GM. 2004. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276.
24. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, Franssen EJ, Lammertsma AA. 2007. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab 27:424-433.